Lincoln Pharmaceuticals Limited (NSE:LINCOLN)
593.20
-6.55 (-1.09%)
Apr 25, 2025, 3:29 PM IST
Lincoln Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Operating Revenue | 5,975 | 5,805 | 5,103 | 4,721 | 4,242 | 3,865 | Upgrade
|
Revenue | 5,975 | 5,805 | 5,103 | 4,721 | 4,242 | 3,865 | Upgrade
|
Revenue Growth (YoY) | 8.54% | 13.76% | 8.09% | 11.30% | 9.75% | 5.56% | Upgrade
|
Cost of Revenue | 2,889 | 2,825 | 2,457 | 2,219 | 2,014 | 1,861 | Upgrade
|
Gross Profit | 3,086 | 2,981 | 2,646 | 2,502 | 2,228 | 2,004 | Upgrade
|
Selling, General & Admin | 1,144 | 1,074 | 981.38 | 845.1 | 756.63 | 734.98 | Upgrade
|
Other Operating Expenses | 1,008 | 904.25 | 767.12 | 692 | 597.41 | 591.2 | Upgrade
|
Operating Expenses | 2,275 | 2,085 | 1,840 | 1,625 | 1,430 | 1,420 | Upgrade
|
Operating Income | 810.97 | 895.83 | 805.47 | 876.98 | 798.01 | 583.39 | Upgrade
|
Interest Expense | -14.97 | -9.46 | -16.38 | -9.2 | -12.02 | -14.97 | Upgrade
|
Interest & Investment Income | 70.28 | 70.28 | 61.71 | 50.28 | 22.65 | 15 | Upgrade
|
Currency Exchange Gain (Loss) | 46.1 | 46.1 | 109.14 | 11.12 | 4.26 | 77.43 | Upgrade
|
Other Non Operating Income (Expenses) | 14.35 | -5.19 | -3.92 | -4.6 | 1.63 | -5.19 | Upgrade
|
EBT Excluding Unusual Items | 926.72 | 997.56 | 956.02 | 924.58 | 814.53 | 655.66 | Upgrade
|
Gain (Loss) on Sale of Investments | 227.85 | 227.85 | 51.35 | 36.12 | 24.5 | 17.96 | Upgrade
|
Gain (Loss) on Sale of Assets | -2.98 | -2.98 | -2.56 | -1.31 | -1.82 | -1.29 | Upgrade
|
Pretax Income | 1,152 | 1,222 | 1,005 | 959.39 | 837.21 | 672.33 | Upgrade
|
Income Tax Expense | 257.91 | 289.38 | 275.81 | 265.84 | 214.71 | 157.66 | Upgrade
|
Earnings From Continuing Operations | 893.68 | 933.05 | 728.99 | 693.55 | 622.5 | 514.67 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | - | -0.27 | Upgrade
|
Net Income | 893.68 | 933.05 | 728.99 | 693.55 | 622.5 | 514.39 | Upgrade
|
Net Income to Common | 893.68 | 933.05 | 728.99 | 693.55 | 622.5 | 514.39 | Upgrade
|
Net Income Growth | 2.40% | 27.99% | 5.11% | 11.41% | 21.02% | 5.60% | Upgrade
|
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade
|
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade
|
Shares Change (YoY) | 0.02% | - | - | - | 0.15% | - | Upgrade
|
EPS (Basic) | 44.61 | 46.58 | 36.40 | 34.63 | 31.08 | 25.72 | Upgrade
|
EPS (Diluted) | 44.61 | 46.58 | 36.40 | 34.63 | 31.08 | 25.72 | Upgrade
|
EPS Growth | 2.37% | 27.98% | 5.11% | 11.41% | 20.84% | 5.60% | Upgrade
|
Free Cash Flow | - | 237.41 | 250.03 | 306.07 | 605.19 | 677.24 | Upgrade
|
Free Cash Flow Per Share | - | 11.85 | 12.48 | 15.28 | 30.21 | 33.86 | Upgrade
|
Dividend Per Share | - | 1.800 | 1.500 | 1.500 | 1.500 | 1.500 | Upgrade
|
Dividend Growth | - | 20.00% | - | - | - | - | Upgrade
|
Gross Margin | 51.65% | 51.34% | 51.84% | 52.99% | 52.52% | 51.84% | Upgrade
|
Operating Margin | 13.57% | 15.43% | 15.78% | 18.57% | 18.81% | 15.10% | Upgrade
|
Profit Margin | 14.96% | 16.07% | 14.29% | 14.69% | 14.67% | 13.31% | Upgrade
|
Free Cash Flow Margin | - | 4.09% | 4.90% | 6.48% | 14.27% | 17.52% | Upgrade
|
EBITDA | 926.92 | 1,001 | 895.8 | 956.29 | 872.01 | 655.12 | Upgrade
|
EBITDA Margin | 15.51% | 17.24% | 17.55% | 20.26% | 20.56% | 16.95% | Upgrade
|
D&A For EBITDA | 115.96 | 104.97 | 90.33 | 79.31 | 74 | 71.74 | Upgrade
|
EBIT | 810.97 | 895.83 | 805.47 | 876.98 | 798.01 | 583.39 | Upgrade
|
EBIT Margin | 13.57% | 15.43% | 15.78% | 18.57% | 18.81% | 15.10% | Upgrade
|
Effective Tax Rate | 22.40% | 23.67% | 27.45% | 27.71% | 25.65% | 23.45% | Upgrade
|
Revenue as Reported | 6,339 | 6,150 | 5,328 | 4,821 | 4,298 | 3,975 | Upgrade
|
Advertising Expenses | - | 10.34 | 11.57 | 0.6 | 0.47 | 1.93 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.